Pfizer and the Hemostasis & Thrombosis Research Society (HTRS) are offering a new Independent Medical Education grant opportunity supporting Visiting Professorships for organizations with limited hemophilia-focused resources and experience.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 10/28/2025
Size of the Grant: $1000 to $10,000
Grant Duration: Grant Duration Not Mentioned
Details:
Clinicians, physician-scientists, and multidisciplinary care teams at recipient organizations will host and coordinate a medical education program led by a distinguished Visiting Professor with expertise matched to specific unmet educational needs surrounding shared decision making (SDM) and emerging therapeutic options in hemophilia.
Funding Information
Individual grant amounts will be up to $7,500.
Target Audiences
Academic clinicians, physician-scientists, and multidisciplinary care teams (MDTs).
Geographical Area
United States.
Eligibility Criteria
- The following may apply: professional medical, nursing, allied health, dental, or pharmacy schools; universities and academic healthcare institutions (both large and small); nonprofit professional organizations or medical societies
- Only organizations are eligible to receive grants (individuals or independent groups of physicians not affiliated with a hospital, academic institution, or professional society are not eligible)
- If the project involves multiple departments within a single institution or is between different institutions, organizations, or associations, each institution, including the requesting organization, must play a defined and relevant role in the project
- The applicant organization must identify an individual to serve as the Project or Program Lead (e.g., the grant coordinator from the applicant organization)
- The Project or Program Lead must be an employee or contractor of the requesting organization
- For projects offering continuing education credit, the requesting organization must supply proof of accreditation.
For more information, visit Pfizer.
